Mosaic ImmunoEngineering Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mosaic ImmunoEngineering Inc. (CPMV) is a development-stage biotechnology company that focuses on advancing and commercializing proprietary immunostimulatory platform technology derived from cowpea mosaic virus (CPMV) for immunotherapies targeting cancer and infectious diseases in humans and veterinary applications; its lead product candidate, MIE-101 (also referred to as MI-O-101), comprises a non-infectious viral nanoparticle administered intratumorally to activate multiple toll-like receptors (TLRs), stimulate innate immune responses, turn "cold" tumors "hot," and enhance efficacy of standard treatments including radiation, chemotherapy, and checkpoint inhibitors like PD-1 across various solid tumor types; the platform also supports modular vaccine development by linking CPMV with antigens for cancer and infectious disease models, including COVID-19, with preclinical data funded by the National Science Foundation and National Institute of Allergy and Infectious Diseases. The company pursues additional oncology product candidates, including clinical-stage necroptosis-inducing vascular disruptive agent (VDA) assets for cancers such as uveal melanoma and retinoblastoma, as well as ocular diseases, complemented by non-exclusive access to AI-driven tools for immunotherapy combinations. Founded in 2020 through a merger with Patriot Scientific Corporation (originally established in 1992) and headquartered at 9114 Adams Avenue, Suite 202, Huntington Beach, California, with operations in Novato, California, Mosaic ImmunoEngineering operates in the healthcare sector serving human and veterinary markets in the United States. In April 2024, the company signed a binding term sheet to acquire clinical necroptosis cancer therapy assets from Oncotelic Therapeutics Inc., involving issuance of up to $30 million in common and preferred stock tied to milestones, technology transfer, and short-term financial support to expand its oncology pipeline amid ongoing preclinical advancement and strategic partnership explorations as of late 2025.
Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting